Jump to content

PSYLO-5001

Add links
From Wikipedia, the free encyclopedia
PSYLO-5001
Clinical data
Other namesPSYLO5001; Psylo-5001; Psylo5001; XYL-5001; XYL5001
Routes of
administration		Unspecified[1]
Drug classSerotonin receptor agonist; Non-hallucinogenic serotonin 5-HT2A receptor agonist

PSYLO-5001 is a non-hallucinogenic serotonin receptor agonist which is under development for the treatment of mental disorders.[1][2][3] Its route of administration is unspecified.[1] The drug is under development by Xylo Bio (formerly Psylo).[1][2][3] As of January 2025, PSYLO-5001 is in the research or preclinical research stage of development.[1][2] Its chemical structure does not yet appear to have been disclosed.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d e f "PSYLO 5001". AdisInsight. 21 January 2025. Retrieved 16 February 2025.
  2. ^ a b c "Delving into the Latest Updates on PSYLO-500X with Synapse". Synapse. 25 January 2025. Retrieved 16 February 2025.
  3. ^ a b Pharmaceutical Technology (1 December 2023). "Partnership deals for psychedelic drugs take a trip with 500% surge in 2023". Pharmaceutical Technology. Retrieved 16 February 2025. Meanwhile, the Australia-based biotech company Psylo signed a co-development partnership deal with Daiichi Sankyo to support the advancement of its discovery and preclinical stage pipeline of non-hallucinogenic psychedelic drugs indicated for the treatment of chronic mental illnesses, including serotonin receptor 2A agonists PSYLO-3001, PSYLO-3002, PSYLO-5001, and PSYLO-1001.
[edit]


Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=PSYLO-5001&oldid=1275992960"